Recent Updates — KPTI
Karyopharm Therapeutics has extended the forbearance period under its Forbearance Agreement and Limited Waiver to Indentures from October 22, 2026, to November 1, 2026. This extension was triggered by Section 19 of the agreement previously entered into on September 10, 2026. The filing does not disclose new financial terms or waivers beyond the timeline adjustment. Karyopharm Therapeutics is a biotechnology company focused on developing therapies for cancer and other diseases.
Karyopharm Therapeutics has entered into an amendment extending the forbearance period under its Forbearance Agreement and Limited Waiver to Indentures. The extension pushes the end date from October 15, 2026, to October 22, 2026. This temporary relief provides additional time for the company to address covenant compliance or negotiate a permanent resolution with lenders. Karyopharm Therapeutics operates in the biotechnology industry, focusing on the discovery and development of therapies targeting nuclear export.
Karyopharm Therapeutics Inc. issued 20,000 shares of 0% Series A Convertible Perpetual Preferred Stock to satisfy a $20.0 million fee obligation under a Forbearance Agreement with lenders. The preferred stock carries a liquidation preference of $1,000 per share and is convertible into common stock at $1.62 per share, subject to a cap of 4,520,000 shares pending stockholder approval. The company operates in the biotechnology industry, focusing on drug discovery and development for cancer and other diseases.
Karyopharm Therapeutics Inc. entered into a Forbearance Agreement with its lenders and noteholders after failing to pay a $15.8 million term loan installment due on September 10, 2026, and missing cash interest payments on its 9.00% Convertible Senior Notes due 2028 and 2029. The agreement forbears creditors from exercising remedies for these defaults until October 15, 2026, or earlier upon bankruptcy, enforcement action, liquidity falling below $10 million, or FDA rejection of the sNDA for selinexor in myelofibrosis. To compensate lenders, Karyopharm issued a Fee Agreement requiring $20 million in fees paid via 20,000 shares of 0% convertible perpetual preferred stock at $1,000 per share, convertible into common stock at $1.62 per share. The company disclosed that absent additional funding or strategic transactions by October 15, it will be unable to continue as a going concern and may seek bankruptcy protection. Karyopharm Therapeutics Inc. operates in the biotechnology industry, developing and commercializing therapies for cancer.
On August 31, 2026, Karyopharm Therapeutics Inc. announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). The application seeks Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis, based on data from the Phase 3 SENTRY trial. Karyopharm requested Priority Review to potentially achieve a six-month review timeline. The company expects FDA feedback on filing acceptance and review timelines during the fourth quarter of 2026 following the standard 60-day filing review period. If approved via the Accelerated Approval pathway, long-term overall survival data from the SENTRY trial will be required to verify clinical benefit and support conversion to traditional approval. Karyopharm Therapeutics Inc. operates in the biotechnology industry, developing and commercializing therapies for cancer.
Karyopharm Therapeutics Inc. reported second quarter 2026 financial results with total revenue of $33.4 million and U.S. XPOVIO net product revenue of $30.8 million, compared to $37.9 million and $29.7 million respectively in the prior year period. The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million and U.S. XPOVIO net product revenue guidance of $115 million to $130 million. Karyopharm announced it remains on track to submit a supplemental New Drug Application (sNDA) for selinexor in combination with ruxolitinib for myelofibrosis in August under the Accelerated Approval pathway, following FDA feedback that spleen volume reduction qualifies as a reasonably likely surrogate endpoint. The company is actively evaluating financing opportunities and strategic alternatives to extend its cash runway beyond September 2026, when a $15.8 million term loan payment is due. Karyopharm Therapeutics Inc. operates in the pharmaceutical industry, developing and commercializing novel cancer therapies.